Before we delve into what the research actually shows, it's worth stating something important upfront. This article does not contain a „how much to take,” „how many mcg per injection,” or „how often to inject” guide for self-administration of CJC-1295 and ipamorelin. This is not an oversight – these compounds are not approved for human use, have no established consumer dosing protocol, and any such guidance would go beyond what a responsible, evidence-based source should offer without medical supervision. What follows, however, is a factual account of the doses actually used in controlled clinical and laboratory studies, along with an explanation of why this type of research dosing cannot be safely translated into a personal dosage chart.
What is the standard dosage of CJC-1295 and Ipamorelin?
There is no standard, medically established dosage for CJC-1295, ipamorelin, or their combination. This is because neither of these compounds has undergone the full clinical research process required to determine an approved, safe dosing regimen for any population. What does exist are specific doses used by researchers in early-stage pharmacological studies, administered under controlled clinical conditions with medical supervision. These figures describe what was tested in a research context – they are not recommendations for personal use.
In the primary human trial for CJC-1295, healthy adult volunteers received single, escalating subcutaneous doses. Researchers identified 30 and 60 microgram per kilogram body weight doses as eliciting a sustained, dose-dependent increase in hormones with the best tolerability profile in that trial. Higher doses were also tested as part of the escalating dose study design, and multiple dosing regimens involved two or three administrations weekly or bi-weekly [1]. For ipamorelin, a separate human pharmacokinetic trial utilized intravenous infusions at five different dose levels. This trial demonstrated the concentration required for half-maximal growth hormone stimulation to be 214 nanomoles per litre, with dose-proportional pharmacokinetics observed across the range studied [2].
These figures are derived from clinical trial protocols designed by scientists to investigate hormonal response curves under medical supervision, with real-time monitoring for adverse events. They are not equivalent to a dosing guide for home use and should not be treated as such, as these trials did not test repeated self-administration for weeks or months in uncontrolled settings. No published study has tested CJC-1295 and ipamorelin administered together as a combination in humans at all.
Dosage of CJC-1295 and Ipamorelin for bodybuilding
There are no clinical trials establishing the dosing of CJC-1295, ipamorelin, or their combination for bodybuilding, muscle growth, or physique purposes. This article will also not provide injection frequency, weekly schedules, or mcg-based recommendations for this purpose. This gap is not a minor oversight. Reviews of the use of injectable peptides in sports and orthopedic medicine have specifically highlighted this as a serious concern, noting that information regarding indications, dosage, frequency, and duration of treatment with these compounds remains unknown – even as their popularity among general consumers and the bodybuilding community has significantly increased [3].
A separate 2026 review concerning the use of peptides in recreational and professional sport went further. It described the supply chain for these products as largely unregulated, with documented risks of contamination and mislabelling. It also specifically noted that supratherapeutic or combined dosing regimens common in bodybuilding communities were not investigated in existing controlled clinical trials, which instead utilised lower, carefully monitored doses of a therapeutic nature [4].
Taking this into account, any specific bodybuilding dosage figures circulating on the internet – whether presented as „typical”, „standard” or „beginner” doses – do not stem from peer-reviewed clinical evidence and should not be treated as validated or safe.
How to dose CJC-1295 with DAC compared to CJC-1295 without DAC
Available clinical dosing data pertains specifically to the DAC-conjugated, long-acting form of CJC-1295. No equivalent human dosing studies exist for the non-DAC version („Mod GRF 1-29″) identified in the peer-reviewed literature reviewed for this article. In the aforementioned human study, the DAC-conjugated form was tested at single doses – with doses of 30 and 60 micrograms per kilogram identified as eliciting sustained, well-tolerated hormonal responses – as well as in repeat dosing regimens by the week or bi-weekly. This reflects the compound’s long half-life of approximately 5.8–8.1 days, meaning less frequent dosing was sufficient to maintain elevated hormone levels over time [1].
Since the -DAC form lacks an albumin-binding mechanism responsible for this prolonged action, one might expect – based on its shorter presumed half-life and structural similarity to natural GHRH – that a different, likely more frequent dosing regimen would be required to elicit a comparable sustained effect. This, however, is an inference based on chemistry and pharmacokinetic principles rather than a finding confirmed by a dedicated human dosing study of the -DAC form.
No published research has been identified that establishes a specific, validated dosing regimen for the DAC-free form, whether used alone or in combination with ipamorelin. This means that any specific frequency or amount provided for this combination is not something this article can responsibly supply.
Why do we not provide practical dosage recommendations?
Readers looking for a specific number of micrograms, millilitres, or an injection schedule might find the absence of this information frustrating. However, providing it would not be responsible given the current state of evidence. CJC-1295 and ipamorelin are not approved by any major regulatory body for human use. There have been no clinical trials establishing a safe or effective self-administration protocol for the purposes of muscle growth, fat loss, or anti-aging. And the doses used in the studies referenced above were administered by clinical researchers under monitored conditions specifically to investigate hormonal response – not to model long-term consumer use.
Reviews covering this peptide class consistently identify unknown dosing, unregulated product quality, and a lack of long-term human safety data as active, unresolved issues, rather than established details that can simply be looked up [3], [4]. Any individual considering the use of these compounds should understand that „dosing tables” circulating in commercial or informal contexts do not derive from peer-reviewed clinical literature and have not been validated for safety or efficacy.
Disclaimer
This content is for educational purposes only and does not constitute medical advice, dosage guidance, or a therapeutic recommendation. CJC-1295 and ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether administered individually or in combination. The dosing information presented here reflects quantities used in controlled clinical and laboratory research settings under medical supervision and is not intended to guide or encourage self-administration. There is no validated consumer dosing protocol for either of these compounds.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[3] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
[4] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1